Navigating Trade, Pharmaceuticals, and AI Challenges

This chapter examines the ramifications of the U.S. trade stance against China, alongside alarming findings regarding the contamination of generic drugs. It advocates for enhanced domestic pharmaceutical manufacturing and quality oversight while reflecting on diplomatic relations between the U.S. and Israel. Additionally, it addresses the complex landscape of artificial intelligence, highlighting the need for regulatory frameworks to navigate its rapid advancements and potential societal impacts.